Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for prostate cancer.

Lawrence Fong1, Eric J Small

  • 1University of California-San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA. Lawrence.fong@ucsf.edu

Current Urology Reports
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Genome biology·2026
Same author

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Cancer·2025
Same author

A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Nature communications·2025
Same author

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.

Nature genetics·2025
Same author

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

JNCI cancer spectrum·2025
Same journal

Effective Mentorship in Urology Fellowship Training: Qualities, Models, and Equity.

Current urology reports·2026
Same journal

Management of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis.

Current urology reports·2026
Same journal

Lower Urinary Tract Symptoms as an Indicator of Occult Neurologic Disease: A System-first Framework for Urologic Practice.

Current urology reports·2026
Same journal

Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis.

Current urology reports·2026
Same journal

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Current urology reports·2026
Same journal

Artificial Intelligence in Urologic Documentation: A Review of Emerging Capabilities and the Ongoing Need for Human Oversight.

Current urology reports·2026
See all related articles

Novel immunotherapies targeting prostate cancer antigens show promise. These treatments, including tumor vaccines, are expanding options beyond traditional androgen deprivation and chemotherapy, generating both immune and clinical responses in patients.

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Advanced prostate cancer treatment relies on androgen deprivation and chemotherapy.
  • Novel therapies are crucial for expanding treatment options.
  • Immunotherapy offers a promising avenue by targeting prostate cancer-specific antigens.

Purpose of the Study:

  • To explore novel immunotherapeutic approaches for advanced prostate cancer.
  • To highlight the potential of tumor vaccines and antigen-targeted therapies.
  • To discuss the role of cancer genomics and proteomics in identifying new targets.

Main Methods:

  • Identification of antigens expressed in prostate tissue and prostate cancer.
  • Utilizing prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen as immunologic targets.

Related Experiment Videos

  • Leveraging innovations in cancer genomics and proteomics for target discovery.

    • Main Results:

    • Immunotherapy can elicit immune responses in patients with advanced prostate cancer.
    • Emerging trials indicate that immunotherapy can also lead to clinical responses.
    • Targeting specific antigens like PSA, PAP, and PSMA is a viable strategy.

    Conclusions:

    • Immunotherapy represents a significant advancement in treating advanced prostate cancer.
    • Future research should focus on optimizing and expanding these immunotherapeutic strategies.
    • Combining immunotherapy with existing treatments may offer enhanced clinical benefits.